ytn2p3ah

Property	Value
?:abstract	BACKGROUND: Pulmonary embolism (PE) has been described in coronavirus disease 2019 (COVID-19) critically ill patients, but the evidence from more heterogeneous cohorts is limited. METHODS: Data were retrospectively obtained from consecutive COVID-19 patients admitted to 13 Cardiology Units in Italy, from March 1st to April 9th, 2020, and followed until in-hospital death, discharge, or April 23rd, 2020. The association of baseline variables with computed tomography-confirmed PE was investigated by Cox hazards regression analysis. The relationship between D-dimer levels and PE incidence was evaluated using restricted cubic splines models. RESULTS: The study included 689 patients (67.3 ± 13.2 year-old, 69.4% males), of whom 43.6% were non-invasively ventilated and 15.8% invasively. 52 (7.5%) had PE over 15 (9-24) days of follow-up. Compared with those without PE, these subjects had younger age, higher BMI, less often heart failure and chronic kidney disease, more severe cardio-pulmonary involvement, and higher admission D-dimer [4344 (1099-15,118) vs. 818.5 (417-1460) ng/mL, p < 0.001]. They also received more frequently darunavir/ritonavir, tocilizumab and ventilation support. Furthermore, they faced more bleeding episodes requiring transfusion (15.6% vs. 5.1%, p < 0.001) and non-significantly higher in-hospital mortality (34.6% vs. 22.9%, p = 0.06). In multivariate regression, only D-dimer was associated with PE (HR 1.72, 95% CI 1.13-2.62; p = 0.01). The relation between D-dimer concentrations and PE incidence was linear, without inflection point. Only two subjects had a baseline D-dimer < 500 ng/mL. CONCLUSIONS: PE occurs in a sizable proportion of hospitalized COVID-19 patients. The implications of bleeding events and the role of D-dimer in this population need to be clarified.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/ytn2p3ah_hasAnnotation_C0019080> <https://research.tib.eu/covid-19/entity/ytn2p3ah_hasAnnotation_C0034065> <https://research.tib.eu/covid-19/entity/ytn2p3ah_hasAnnotation_C1976853>
?:creator	<https://research.tib.eu/covid-19/entity/Ameri%2C_Pietro%3B_Inciardi%2C_Riccardo_M%3B_Di_Pasquale%2C_Mattia%3B_Agostoni%2C_Piergiuseppe%3B_Bellasi%2C_Antonio%3B_Camporotondo%2C_Rita%3B_Canale%2C_Claudia%3B_Carubelli%2C_Valentina%3B_Carugo%2C_Stefano%3B_Catagnano%2C_Francesco%3B_Danzi%2C_Giambattista%3B_Dalla_Vecchia%2C_Laura%3B_Giovinazzo%2C_Stefano%3B_Gnecchi%2C_Massimiliano%3B_Guazzi%2C_Marco%3B_Iorio%2C_Anita%3B_La_Rovere%2C_Maria_Teresa%3B_Leonardi%2C_Sergio%3B_Maccagni%2C_Gloria%3B_Mapelli%2C_Massimo%3B_Margonato%2C_Davide%3B_Merlo%2C_Marco%3B_Monzo%2C_Luca%3B_Mortara%2C_Andrea%3B_Nuzzi%2C_Vincenzo%3B_Piepoli%2C_Massimo%3B_Porto%2C_Italo%3B_Pozzi%2C_Andrea%3B_Provenzale%2C_Giovanni%3B_Sarullo%2C_Filippo%3B_Sinagra%2C_Gianfranco%3B_Tedino%2C_Chiara%3B_Tomasoni%2C_Daniela%3B_Volterrani%2C_Maurizio%3B_Zaccone%2C_Gregorio%3B_Lombardi%2C_Carlo_Mario%3B_Senni%2C_Michele%3B_Metra%2C_Marco>
?:journal	Clin._res._cardiol
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/ytn2p3ah_HAS_C0034065_ASSOCIATED_WITH_C0060323> <https://research.tib.eu/covid-19/entity/ytn2p3ah_HAS_C1609165_ASSOCIATED_WITH_C0034065>
?:source	WHO
?:title	Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#898011
?:year	2020

Property

Value

?:abstract

BACKGROUND: Pulmonary embolism (PE) has been described in coronavirus disease 2019 (COVID-19) critically ill patients, but the evidence from more heterogeneous cohorts is limited. METHODS: Data were retrospectively obtained from consecutive COVID-19 patients admitted to 13 Cardiology Units in Italy, from March 1st to April 9th, 2020, and followed until in-hospital death, discharge, or April 23rd, 2020. The association of baseline variables with computed tomography-confirmed PE was investigated by Cox hazards regression analysis. The relationship between D-dimer levels and PE incidence was evaluated using restricted cubic splines models. RESULTS: The study included 689 patients (67.3 ± 13.2 year-old, 69.4% males), of whom 43.6% were non-invasively ventilated and 15.8% invasively. 52 (7.5%) had PE over 15 (9-24) days of follow-up. Compared with those without PE, these subjects had younger age, higher BMI, less often heart failure and chronic kidney disease, more severe cardio-pulmonary involvement, and higher admission D-dimer [4344 (1099-15,118) vs. 818.5 (417-1460) ng/mL, p < 0.001]. They also received more frequently darunavir/ritonavir, tocilizumab and ventilation support. Furthermore, they faced more bleeding episodes requiring transfusion (15.6% vs. 5.1%, p < 0.001) and non-significantly higher in-hospital mortality (34.6% vs. 22.9%, p = 0.06). In multivariate regression, only D-dimer was associated with PE (HR 1.72, 95% CI 1.13-2.62; p = 0.01). The relation between D-dimer concentrations and PE incidence was linear, without inflection point. Only two subjects had a baseline D-dimer < 500 ng/mL. CONCLUSIONS: PE occurs in a sizable proportion of hospitalized COVID-19 patients. The implications of bleeding events and the role of D-dimer in this population need to be clarified.

is ?:annotates of